Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL-3862 + timolol is a combination drug consisting of AL-3862 (a code name for an investigational or less well-characterized compound) and timolol. Timolol is a non-selective beta-adrenergic blocker used primarily to lower intraocular pressure in conditions such as open-angle glaucoma and ocular hypertension. It works by blocking beta(1)-adrenergic receptor in the heart and beta(2)-adrenergic receptor in vascular and bronchial smooth muscle to reduce aqueous humor production within the eye[4][5]. The mechanism of action for AL-3862 is not established from available sources. Combination therapies with timolol are commonly developed to enhance intraocular pressure reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AL-3862 + timolol.